A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas (pages 4905–4915)
William T. Couldwell, Amy A. Surnock, Alfonso J. Tobia, Bernard E. Cabana, Charles B. Stillerman, Peter A. Forsyth, Alan J. Appley, Alexander M. Spence, David R. Hinton and Thomas C. Chen
Article first published online: 31 MAR 2011 | DOI: 10.1002/cncr.26123
Hypericin is a potent inhibitor of glioma growth in a dose-related manner in vitro and has exhibited marked inhibition of growth, motility, and invasion in the low-micromolar concentration range. The results from this phase 1/2 open-label, sequential dose escalation/de-escalation tolerance study of synthetic oral hypericin in patients with recurrent malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) indicated that it is well tolerated and exhibits efficacy in this difficult patient group, suggesting that further trials of hypericin as adjuvant therapy for patients with malignant glioma are warranted.